KERX Keryx Biopharmaceuticals, Inc. (delisted)

Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 33rd Annual J.P. Morgan Healthcare Conference, being held January 12-15, at the Westin-St. Francis Hotel in San Francisco, California.

Mr. Bentsur's presentation will take place on Tuesday, January 13th at 4:00 p.m. PT (7:00 p.m. ET).

A live audio webcast of Mr. Bentsur's presentation will be accessible within the Investor Relations section of the Company's website at http://investors.keryx.com. An archived version of this webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company's lead product, Auryxia™ (ferric citrate), was approved by the U.S. Food and Drug Administration on September 5, 2014.

For additional company information, including full prescribing information for Auryxia, please visit www.keryx.com.

CONTACT: Amy Sullivan, Vice President - Corporate Development
         and Public Affairs
         Keryx Biopharmaceuticals, Inc.
         Tel: 617.466.3447
         E-mail: amy.sullivan@keryx.com